Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Latest filing published 15 Jul 2022 for VistaGen Therapeutics, Inc., €3,569. Read the official filing
Insider track record
Disclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Mark Alan Smith: trading record in brief
This profile gathers the share dealings of Mark Alan Smith in VistaGen Therapeutics, Inc., where the filings describe the role as senior executive. In total, 3 filings cover trades dated from 30 June 2021 to 30 June 2022.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
The newest entry dates from 15 July 2022: a share grant of €3,569, in VistaGen Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Mark Alan Smith
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations3 total
5,000 shares@ US$0.74819.0% of flowCommon StockSEC:0001415889-22-007687:0
2,655 shares@ US$1.657534.8% of flowCommon StockSEC:0001415889-22-000046:0
2,260 shares@ US$1.946533.2% of flowCommon StockSEC:0001415889-21-003388:0
3 of 3 declarations
